SFA Intervention Surveillance: Where Is the Benefit?  by Wuamett, Joseph et al.
JOURNAL OF VASCULAR SURGERY
98S Abstracts May Supplement 2013amputation. The impact of social context is tested by
including patients from the US and Tanzania (TNZ).
Methods: MLE amputees were recruited from US and
TNZ sites in a prospective study. Data collected included
demographic, social integration (CHART), walking func-
tion (Six Minute Walk Test) and QoL (EQ5D). c2 and
ANOVA tests were used to assess association between social
integration and outcomes. Multivariable logistic regression
analysis, was performed to assess the role of social context.
Results: Of the 90 enrolled patients, 50 (56%) were
from the US, 58 (64%) were male, with a mean age of
64.4 years. Patients with high social integration had a trend
toward improved function deﬁned by a score of 171 meters
or better (36% v 66% v 74%; P ¼ .055) and signiﬁcantly
higher mean EQ5D scores (0.65 v 0.70 v 0.79; P ¼
.021). Findings were more dramatic in the US sub-group
for both function (17% v 38% v 74%; P ¼ .008) and
QoL (0.52 v 0.58 v 0.79; P ¼ .001). In a multivariate anal-
ysis, the TNZ site was not associated with less favorable
function (P ¼ .783) or QoL (P ¼ .364).
Conclusions: In the US population, increased social
integration is associated with both improved function and
quality of life outcomes among amputees. This effect is
attenuated in TNZ, likely due to differences in social
context. Steps should be taken to identify and aid amputees
with poor social integration in the US and factors associ-
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Objectives: While many vascular surgeons follow the
algorithm of postoperative bypass vascular evaluation
including non-invasive ﬂow studies (NIFS) and bypass graft
duplex (BGD) at 1, 3, 6 months and annually thereafter,
the data surrounding this recommendation is low. It has
been shown that routine BGD scanning following autoge-
nous lower extremity bypass has not proven to be cost-
effective. The TASC II document recommends a biannual
assessment of exercise NIFS for 2 years postoperatively as
level C evidence. Superﬁcial Femoral Artery (SFA) Percuta-
neous Transluminal Angioplasty/Stent (PTA/S) trials have
required similar schedules of postprocedure evaluation. We
chose to evaluate the beneﬁt of postprocedure imaging.
Methods: We undertook a retrospective review of
a prospective database looking at SFA intervention. The
number of follow up visits, frequency of changes in exam,
changes in postprocedure NIFS and BGD were analyzed.
Results: 104 patients had SFA interventions (46 PTA,
46 PTA/stent, 8 atherectomy, 4 PTA/lysis). Initial studies
(NIFS and/or BGD) within 1-7 weeks showed a change
(ABI < .7 and/or 4:1 peak systolic velocity ratio) in
3.1% of cases, at 3 months an additional 41% showed
change (RR > 1.0; P < .05); at 6 months only an addi-
tional 8% showed change (RR < 1.0; P > 0.05). Kaplan
Meier analysis revealed a lack of signiﬁcance at the 1 year
mark and beyond due decreased follow up.
Conclusions: Of the 547 postprocedure perfusion
assays performed in these 104 patients the statistically
signiﬁcant interval appears to be at the 3 month post-
procedure visit. While the initial study acts as a baseline
the utility of further testing does not appear to add signif-
icant additional information on a cohort basis. Like algo-
rithms for distal bypass there did appear to be better
correlation when coupled with return of symptoms and
or change in physical exam.
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Objectives: Despite patent bypass grafts, some
patients receive major amputations (MA). We analyzed
the frequency and predictive factors leading to MA in the
presence of patent lower extremity bypass grafts (LEB).
Methods: Data from PREVENT III, a large prospec-
tive randomized trial of 1404 patients who underwent LEB
for critical limb ischemia (CLI) was queried for outcomes.
The primary endpoint was MA with patent (PMA) or
